NO20034149D0 - Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel - Google Patents

Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel

Info

Publication number
NO20034149D0
NO20034149D0 NO20034149A NO20034149A NO20034149D0 NO 20034149 D0 NO20034149 D0 NO 20034149D0 NO 20034149 A NO20034149 A NO 20034149A NO 20034149 A NO20034149 A NO 20034149A NO 20034149 D0 NO20034149 D0 NO 20034149D0
Authority
NO
Norway
Prior art keywords
triazaspiro
active ingredient
medicines containing
undecane derivatives
undecane
Prior art date
Application number
NO20034149A
Other languages
English (en)
Other versions
NO20034149L (no
Inventor
Hiroaki Mitsuya
Kenji Maeda
Shiro Shibayama
Yoshikazu Takaoka
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of NO20034149D0 publication Critical patent/NO20034149D0/no
Publication of NO20034149L publication Critical patent/NO20034149L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NO20034149A 2001-03-19 2003-09-17 Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel NO20034149L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001079611 2001-03-19
PCT/JP2002/002553 WO2002074769A1 (fr) 2001-03-19 2002-03-18 Medicaments contenant comme principe actif des derives du triazaspiro [5.5] undecane

Publications (2)

Publication Number Publication Date
NO20034149D0 true NO20034149D0 (no) 2003-09-17
NO20034149L NO20034149L (no) 2003-11-19

Family

ID=18936022

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034149A NO20034149L (no) 2001-03-19 2003-09-17 Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel

Country Status (17)

Country Link
US (1) US7285552B2 (no)
EP (1) EP1378509A4 (no)
JP (1) JPWO2002074769A1 (no)
KR (1) KR20030093248A (no)
CN (1) CN1533390A (no)
BR (1) BR0208229A (no)
CA (1) CA2441162A1 (no)
CZ (1) CZ20032532A3 (no)
HU (1) HUP0400241A2 (no)
IL (1) IL157940A0 (no)
MX (1) MXPA03008528A (no)
NO (1) NO20034149L (no)
NZ (1) NZ528270A (no)
PL (1) PL364469A1 (no)
RU (1) RU2003128075A (no)
WO (1) WO2002074769A1 (no)
ZA (1) ZA200307318B (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1291988C (zh) * 2001-03-19 2006-12-27 小野药品工业株式会社 三氮杂螺[5,5]十一烷衍生物及包含其作为活性成分的药物组合物
TW200413372A (en) * 2002-09-18 2004-08-01 Ono Pharmaceutical Co Derivatives of triazaspiro [5.5] undecane and medicants using such derivatives as effective ingredient
TW200413371A (en) 2002-09-18 2004-08-01 Ono Pharmaceutical Co Novel crystal of triazaspiro [5.5]undecane derivatives
US20060251651A1 (en) * 2002-12-13 2006-11-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist which bind to a strong binding site of chemokine receptor
WO2004094424A1 (ja) * 2003-04-21 2004-11-04 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその用途
WO2006022454A1 (ja) * 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
US20060160859A1 (en) * 2004-12-01 2006-07-20 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and GW873140
WO2010009196A1 (en) * 2008-07-15 2010-01-21 Temple University Of The Commonwealth System Of Higher Education Synthesis of bis-peptides oligomers comprising at least one n-substituted diketopiperazine as structural moiety
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010018131A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
KR101649881B1 (ko) 2008-08-11 2016-08-30 글락소스미스클라인 엘엘씨 신규의 아데닌 유도체
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
ES2525826T3 (es) 2010-02-10 2014-12-30 Glaxosmithkline Llc Maleato de 6-amino-2-{[(1s)-1-metilbutil]-oxi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8H-purin-8-ona
EP2624696B1 (en) 2010-10-06 2016-12-21 Glaxosmithkline LLC Benzimidazole derivatives as pi3 kinase inhibitors
WO2013012649A1 (en) 2011-07-15 2013-01-24 Glaxosmithkline Llc Azaindole compounds and methods for treating hiv
WO2013043553A1 (en) 2011-09-22 2013-03-28 Glaxosmithkline Llc Pyrrolopyridinone compounds and methods for treating hiv
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
EP2877468B1 (en) 2012-07-12 2017-08-23 ViiV Healthcare UK Limited Compounds and methods for treating hiv
EP3107915B1 (en) 2014-02-20 2017-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon
JP2017533925A (ja) 2014-11-13 2017-11-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体
TW201708210A (zh) 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
AU2016285483B2 (en) 2015-07-02 2018-07-19 Glaxosmithkline Intellectual Property Development Limited Inhibitors of indoleamine 2,3-dioxygenase
WO2017017609A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
JP2018521107A (ja) 2015-07-28 2018-08-02 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ感染を予防または治療するためのベツイン誘導体
KR20180054826A (ko) 2015-09-24 2018-05-24 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 성숙 억제 활성을 갖는 화합물
MA52157A (fr) 2015-12-03 2021-02-17 Glaxosmithkline Ip Dev Ltd Dinucléotides cycliques de purine utilisés comme modulateurs de sting
US10583140B2 (en) 2016-01-27 2020-03-10 Glaxosmithkline Intellectual Property Development Limited Ingenol analogs, pharmaceutical compositions and methods of use thereof
EP3440072B1 (en) 2016-04-07 2020-01-29 GlaxoSmithKline Intellectual Property Development Ltd Heterocyclic amides useful as protein modulators
CR20200045A (es) 2016-04-07 2020-03-11 Glaxosmithkline Ip Dev Ltd AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472)
EP3452483B1 (en) 2016-05-05 2020-04-01 GlaxoSmithKline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
WO2018002902A1 (en) 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
UY37463A (es) 2016-11-02 2018-05-31 Glaxosmithkline Ip No 2 Ltd Proteínas de unión
UY37710A (es) 2017-05-02 2018-11-30 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
AU2018344902B2 (en) 2017-10-05 2021-06-03 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING) useful in treating HIV
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
WO2019087016A1 (en) 2017-10-30 2019-05-09 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
JP2021515771A (ja) 2018-03-07 2021-06-24 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Ｈｉｖ療法に有用な化合物
WO2019198024A1 (en) 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
AR115936A1 (es) 2018-08-09 2021-03-17 Glaxosmithkline Ip No 2 Ltd Compuestos útiles en terapia del vih
JP2021536444A (ja) 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Ｈｉｖ療法に有用な化合物
AU2019390729B2 (en) 2018-11-30 2022-08-11 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
CA3132112A1 (en) 2019-03-06 2020-09-10 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
EP3969438A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
US20220259252A1 (en) 2019-08-08 2022-08-18 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
US20220298160A1 (en) 2019-08-28 2022-09-22 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
WO2022182604A1 (en) 2021-02-23 2022-09-01 Viiv Healthcare Company Compounds useful in hiv treatment
WO2023230541A1 (en) 2022-05-27 2023-11-30 Viiv Healthcare Company Piperazine derivatives useful in hiv therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS231227B1 (en) 1982-10-01 1984-10-15 Evzen Kasafirek 2,5-pierazindion derivatives
WO1993013101A1 (en) * 1991-12-27 1993-07-08 Yoshitomi Pharmaceutical Industries, Ltd. Pyridonecarboxylate compound, pharmaceutical use thereof, and spiro compound
AU713235B2 (en) 1995-09-29 1999-11-25 Cor Therapeutics, Inc. Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
NZ519183A (en) 1999-12-03 2005-02-25 Ono Pharmaceutical Co Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient
FR2804882B1 (fr) 2000-02-11 2002-05-10 Air Liquide Procede de compression d'air atmospherique
CN1291988C (zh) 2001-03-19 2006-12-27 小野药品工业株式会社 三氮杂螺[5,5]十一烷衍生物及包含其作为活性成分的药物组合物

Also Published As

Publication number Publication date
US20040106619A1 (en) 2004-06-03
CA2441162A1 (en) 2002-09-26
PL364469A1 (en) 2004-12-13
HUP0400241A2 (hu) 2004-06-28
BR0208229A (pt) 2004-03-09
EP1378509A4 (en) 2009-03-25
EP1378509A1 (en) 2004-01-07
ZA200307318B (en) 2004-07-29
NO20034149L (no) 2003-11-19
CN1533390A (zh) 2004-09-29
IL157940A0 (en) 2004-03-28
NZ528270A (en) 2005-10-28
RU2003128075A (ru) 2005-04-10
CZ20032532A3 (en) 2004-03-17
MXPA03008528A (es) 2004-06-30
JPWO2002074769A1 (ja) 2004-07-08
KR20030093248A (ko) 2003-12-06
WO2002074769A1 (fr) 2002-09-26
US7285552B2 (en) 2007-10-23

Similar Documents

Publication Publication Date Title
NO20034149L (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
PL376154A1 (en) Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
AU2002238947A1 (en) Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient
ITTO20010005A0 (it) Formulazione farmaceutica.
NO20041567L (no) 1,8-nafthyridinderivater som antidiabetiske midler
MXPA03006884A (es) Formulacion farmaceutica.
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
NO20015477L (no) 4,5,6,7-tetrahydroindazolderivater som antitumormidler
NO20002217L (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
MA26385A1 (fr) Derives de 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate
MXPA03007641A (es) Formulacion farmaceutica.
DK1401841T3 (da) Substituerede 1-oxa-2,8-diaza-spiro[4,5]dec-2-en-derivater som lægemidler mod smerte
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
PL360294A1 (en) Propane-1,3-dione derivatives
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
DK1389213T3 (da) 3,7-Diazabicyclo[3.3.1]formuleringer som antiarytmiske forbindelser
DK1118610T3 (da) Benzensulfonamid-derivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
IS6989A (is) 3,7-díasabísýkló [3.3.1] blöndur sem efnasambönd gegn sláttarglöpum
NO20041878L (no) Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel.
NO20030474D0 (no) Demens-legemiddel som inneholder 2-aryl-8- oksodihydropurinderivater som denaktive bestanddel
AU2001242819A1 (en) Pharmaceutical compositions containing as the active ingredient nitropyrimidine derivatives or salts thereof